# US 2021/0275629 A1 · Compositions comprising sel1-derived peptides and methods of treatment/prevention of excess oxalate levels and associated conditions/diseases therewith

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275629 A1
- Document ID: US20210275629A1
- Status: Published application
- Kind: A1
- Application number: 17/260,690
- Filed: 2019-07-18
- Published: 2021-09-09
- Earliest claimed: 2018-07-18
- Assignees: The University of Chicago
- Applicants: The University of Chicago
- Inventors: Hatim A. Hassan; Donna Arvans
- Web page: https://patentgrep.com/patent/US20210275629A1

## CPC

- A61K 38/164: {from bacteria}
- C07K 14/47: from mammals
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61P 13/04: for urolithiasis
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compositions comprising Sel1-derived peptides thereof, and method of use thereof for the treatment/prevention excess oxalate levels and conditions and diseases related thereto. In particular, peptides comprise Sel-like repeat (SLR) domains and/or tetratricopeptide (TPR) domains and may be linked together or with other peptides or polypeptides to treat/prevent diseases/conditions related to excess oxalate levels, such as hyperoxaluria and/or hyperoxalemia.

## Claims

### Claim 1

A composition comprising a Sel1-derived peptide sequence with at least 60% sequence identity to one of SEQ ID NOs: 5-46, wherein the composition is not a product of nature.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the Sel1-derived peptide sequence has less than 100% sequence identity to SEQ ID NOs: 5-46.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the Sel1-derived peptide sequence is fused to a second peptide or polypeptide sequence.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the second peptide or polypeptide sequence is a carrier moiety, therapeutic moiety, or detectable moiety,

### Claim 5 (depends on 1)

The composition of claim 1, wherein the composition comprises 2 or more Sel1-derived peptide sequences with at least 60% sequence identity to one of SEQ ID NOs: 5-46.

### Claim 6 (depends on 4, 5)

The composition of claim 4 or claim 5, wherein the Sel1-derived peptide sequences are fused directly or indirectly to each other.

### Claim 7 (depends on 5, 6)

The composition of claim 5 or claim 6, wherein the Sel1-derived peptide sequences are not fused to each other.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The composition of one or claims 1-7, wherein:
(i) one or more of the amino acid residues in the peptide sequence(s) are D-enantiomers,
(ii) the peptide sequence(s) comprise a one or more unnatural amino acids,
(iii) the peptide sequence(s) comprise a one or more amino acid analogs, and/or
(iv) the peptide sequence(s) comprise a one or more peptoid amino acids.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The composition of one or claims 1-8, wherein the peptide sequence(s) or an amino acid therein comprises a modification selected from the group consisting of phosphorylation, glycosylation, ubiquitination, S-nitrosylation, methylation, N-acetylation, C-terminal amidation, cyclization, substitution of natural L-amino acids with non-natural D-amino acids, lipidation, lipoylation, deimination, eliminylation, disulfide bridging, isoaspartate formation, racemization, glycation; carbamylation, carbonylation, isopeptide bond formation, sulfation, succinylation, S-sulfonylation, S-sulfinylation, S-sulfenylation, S-glutathionylation, pyroglutamate formation, propionylation, adenylylation, nucleotide addition, iodination, hydroxylation, malonylation, butyrylation, amidation, alkylation, acylation, biotinylation, carbamylation, oxidation, pegylation, and any other applicable peptide modification.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The composition of one of claim 1-9, wherein the peptide sequence(s) exhibit enhanced stability relative to one of SEQ ID NOs: 5-46.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The composition of one of claim 1-10, wherein the peptide sequence(s) exhibit enhanced oxalate-transport stimulation relative to one of SEQ ID NOs: 5-46.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A pharmaceutical composition comprising a composition of one of claims 1-11 and a pharmaceutically-acceptable carrier.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, further comprising one or more additional therapeutic agents.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of stimulating oxalate transport comprising administering to a subject a composition of one of claims 1-13.

### Claim 15 (depends on 14)

The method of claim 14, wherein administration comprises rectal administration, oral administration, and/or injection.

### Claim 16 (depends on 14, 15)

The method of one of claims 14-15, wherein the subject suffers from or is at risk for hyperoxaluria and/or hyperoxalemia.

### Claim 17 (depends on 14, 15)

The method of one of claims 14-15, wherein the subject's risk of the risk of calcium oxalate kidney stones, nephrocalcinosis, oxalate nephropathy, end stage renal disease, chronic kidney disease, and/or systemic oxalosis is lowered by the method.
